Maude Tessier - 18 Jan 2022 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role: Chief Business Officer
Signature: /s/ Douglas R. Carlson, as Attorney-in-Fact for Maude Tessier
Issuer symbol: IKNA
Transactions as of: 18 Jan 2022
Net transactions value: +$253,800
Form type: 4
Filing time: 20 Jan 2022, 15:30:43 UTC
Next filing: 04 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IKNA	Common Stock	Options Exercise	$114,410	+38,915	+135%	$2.94	67,707	18 Jan 2022	Direct
transaction	IKNA	Common Stock	Options Exercise	$102,115	+24,606	+36%	$4.15	92,313	18 Jan 2022	Direct
transaction	IKNA	Common Stock	Options Exercise	$37,275	+8,265	+9%	$4.51	100,578	18 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKNA	Stock Option (Right to Buy)	Options Exercise	$0	-38,915	-87%	$0.000000	5,560	18 Jan 2022	Common Stock	38,915	$2.94	Direct	F1
transaction	IKNA	Stock Option (Right to Buy)	Options Exercise	$0	-24,606	-69%	$0.000000	11,186	18 Jan 2022	Common Stock	24,606	$4.15	Direct	F2
transaction	IKNA	Stock Option (Right to Buy)	Options Exercise	$0	-8,265	-22%	$0.000000	28,963	18 Jan 2022	Common Stock	8,265	$4.51	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option vested and became exercisable on July 16, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2	25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3	25% of this option vested and became exercisable on December 6, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.